Author: Benzinga Newsdesk | November 12, 2024 05:22pm
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.45) by 6.67 percent. This is a 12.5 percent increase over losses of $(0.48) per share from the same period last year.